193 related articles for article (PubMed ID: 28548702)
1. p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.
Lummus SC; Donson AM; Gowan K; Jones KL; Vibhakar R; Foreman NK; Kleinschmidt-DeMasters BK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28548702
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
5. SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.
Kleinschmidt-DeMasters BK; Donson AM; Richmond AM; Pekmezci M; Tihan T; Foreman NK
J Neuropathol Exp Neurol; 2016 Apr; 75(4):295-8. PubMed ID: 26945037
[TBL] [Abstract][Full Text] [Related]
6. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
7. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
9. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.
Baroni LV; Sundaresan L; Heled A; Coltin H; Pajtler KW; Lin T; Merchant TE; McLendon R; Faria C; Buntine M; White CL; Pfister SM; Gilbert MR; Armstrong TS; Bouffet E; Kumar S; Taylor MD; Aldape KD; Ellison DW; Gottardo NG; Kool M; Korshunov A; Hansford JR; Ramaswamy V
Neuro Oncol; 2021 Aug; 23(8):1360-1370. PubMed ID: 33580238
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
11. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
12. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
[TBL] [Abstract][Full Text] [Related]
13. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN
Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527
[TBL] [Abstract][Full Text] [Related]
18. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
[TBL] [Abstract][Full Text] [Related]
19. Treatment implications of posterior fossa ependymoma subgroups.
Ramaswamy V; Taylor MD
Chin J Cancer; 2016 Nov; 35(1):93. PubMed ID: 27846874
[TBL] [Abstract][Full Text] [Related]
20. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B.
Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
